Compare NEXN & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEXN | ANNX |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 367.2M | 334.1M |
| IPO Year | 2021 | 2020 |
| Metric | NEXN | ANNX |
|---|---|---|
| Price | $6.46 | $4.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $12.13 | ★ $16.60 |
| AVG Volume (30 Days) | 434.2K | ★ 3.3M |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 237.45 | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $376,353,000.00 | N/A |
| Revenue This Year | $5.43 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.41 | ★ N/A |
| Revenue Growth | ★ 7.80 | N/A |
| 52 Week Low | $6.08 | $1.29 |
| 52 Week High | $12.60 | $5.66 |
| Indicator | NEXN | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 34.86 | 67.57 |
| Support Level | $6.35 | $4.01 |
| Resistance Level | $6.71 | $4.64 |
| Average True Range (ATR) | 0.26 | 0.37 |
| MACD | 0.06 | 0.05 |
| Stochastic Oscillator | 29.70 | 81.06 |
Nexxen International Ltd is a globalized and flexible advertising technology platform with deep expertise in data and advanced TV that helps empower advertisers, agencies, digital publishers and broadcasters to achieve desired outcomes, including increased efficiency and returns, across the media supply chain. It is a demand-side platform (DSP), supply-side platform (SSP), ad server, and data management platform (DMP) and also delivers a flexible and unified technology stack with and exclusive data at its core. Company operates in America, APAC, EMEA, regions, with majority revenue from America.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.